Journal of Clinical Oncology recently published ASCO's update to its guideline on the use of bone-modifying agents for patients with bone metastases, the scope of which was narrowed to the use of bone-modifying agents for patients with evidence of bone metastases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051857 | PMC |
| http://dx.doi.org/10.1200/JOP.2011.000212 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe hypophosphataemia following denosumab administration successfully managed using a calcimimetic agent.
BMJ Case Rep
January 2025
Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan.
Denosumab, an anti-RANKL antibody, induces bone metabolism to a low-turnover bone status by arresting osteoclast activity. Frequent adverse events include infusion reactions, fever and hypocalcaemia but not hypophosphataemia. We report a case of severe hypophosphataemia associated with secondary hyperparathyroidism following denosumab administration in a young boy with recurrent osteosarcoma who was successfully treated with evocalcet.
View Article and Find Full Text PDFPrognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study.
World J Orthop
December 2024
Department of Orthopaedic Surgery, The University of Tokyo, Bunkyo-ku 113-8655, Tokyo, Japan.
Background: Accurate data on the prognosis of bone metastases are necessary for appropriate treatment. Immune checkpoint inhibitors (ICIs) are widely used in the treatment of gene mutation-negative non-small cell lung cancer (GMN-NSCLC).
Aim: To investigate the prognostic factors in patients with bone metastases from GMN-NSCLC following ICI use.
High Fracture Risk of Femoral Bone Metastasis Treated with Palliative Radiotherapy in Recent Years.
Curr Oncol
November 2024
Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Chiba, Japan.
Bone-modifying agents (BMAs) have been widely used to reduce skeletal-related events, including pathological fractures. Herein, we aimed to clarify the incidence of pathological fractures caused by high-risk femoral bone metastases after palliative radiotherapy (RT) in the BMA era and evaluate the necessity of prophylactic surgical stabilization. We assessed 90 patients with high-risk femoral bone metastases, indicated by Mirels' scores ≥ 8, without pathological fractures and surgical fixations, who received palliative RT at our institution between January 2009 and December 2018.
View Article and Find Full Text PDFAdministration and cancer-control outcomes of bone-modifying agents in real-world patients with metastatic castration-resistant prostate cancer.
JBMR Plus
January 2025
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, 63010, Germany.
Hormonal agents administered for metastatic castration-resistant prostate cancer (mCRPC) may lead to osteoporosis, skeletal events, reduced quality of life, and even reduced overall survival (OS). Bone-modifying agents may prevent those events but their effect on cancer-control outcomes remains uncertain. Relying on our institutional tertiary-care database, we explored the effect of bone-modifying agents (bisphosphonates such as zoledronic acid and denosumab) on OS and progression-free survival in patients with mCRPC with at least 1 bone metastasis using Kaplan-Meyer estimates and Cox regression models.
View Article and Find Full Text PDFRisk Factors and Impact on Survival of Pathological Fractures in Patients With Humeral Metastasis.
Cureus
November 2024
Department of Orthopaedic Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, JPN.
Background Bone metastases often cause pathological fractures and impair patients' quality of life and survival. Although several studies have been conducted on pathological fractures in the femur and spine, limited research has been done on the upper limbs. This study aimed to reveal the risk factors and determine how pathological fractures impact survival in patients with humeral metastasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!